Open access · US-GOV
via ClinicalTrials.gov Clinical trial
An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration
Authors not listed
Chengdu Kanghong Biotech Co., Ltd. · 2011
Abstract
This study is designed to evaluate the effect of Conbercept therapy on visual acuity and anatomic outcomes and safety observed in subjects with very low vision secondary to wet age-related macular degeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2011). An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration. <em>Chengdu Kanghong Biotech Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT02098720
Vancouver
Anonymous. An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration. Chengdu Kanghong Biotech Co., Ltd.. 2011.
BibTeX
@misc{anon2011AnOpen,
title = {An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration},
author = {Anonymous},
journal = {Chengdu Kanghong Biotech Co., Ltd.},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
OccuLogix 2005
Open access · US-GOV
A Multicenter, Open Label, Prospective Study to Determine Safety and Efficacy Over an Additional 12-Month Period With Non-Exudative Age-Related Macular Degeneration (With Follow-on to 12-Months)
Advanced Drug Delivery Reviews 2005
Citation only
Wet age-related macular degeneration
VIS, Inc. 2025
Open access · US-GOV
Vision Improvement for Patients With Age-Related Macular Degeneration
University of Iowa 2003
Open access · US-GOV
Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension
Alcon Research 2005
Open access · US-GOV
Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)
EyebioKorea, Inc. 2024
Open access · US-GOV